Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Among authors: scemama m. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5.
Daniels S, Caprio S, Chaudhari U, Manvelian G, Baccara-Dinet MT, Brunet A, Scemama M, Loizeau V, Bruckert E. Daniels S, et al. Among authors: scemama m. J Clin Lipidol. 2020 Sep-Oct;14(5):741. doi: 10.1016/j.jacl.2020.08.011. J Clin Lipidol. 2020. PMID: 33138961 Free article. No abstract available.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. Among authors: scemama m. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Ostadal P, et al. Among authors: scemama m. Lancet Diabetes Endocrinol. 2022 May;10(5):330-340. doi: 10.1016/S2213-8587(22)00043-2. Epub 2022 Apr 1. Lancet Diabetes Endocrinol. 2022. PMID: 35378068 Clinical Trial.
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
Bruckert E, Caprio S, Wiegman A, Charng MJ, Zárate-Morales CA, Baccara-Dinet MT, Manvelian G, Ourliac A, Scemama M, Daniels SR. Bruckert E, et al. Among authors: scemama m. Arterioscler Thromb Vasc Biol. 2022 Dec;42(12):1447-1457. doi: 10.1161/ATVBAHA.122.317793. Epub 2022 Nov 3. Arterioscler Thromb Vasc Biol. 2022. PMID: 36325897 Free PMC article. Clinical Trial.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, Fazio S, Fras Z, Goodman SG, Harrington RA, Jukema JW, Manvelian G, Pordy R, Ray KK, Scemama M, White HD, Steg PG; ODYSSEY OUTCOMES Investigators. Schwartz GG, et al. Among authors: scemama m. Eur Heart J. 2023 Mar 5;44(16):1408-17. doi: 10.1093/eurheartj/ehad144. Online ahead of print. Eur Heart J. 2023. PMID: 36879424 Free PMC article.
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Steg PG, et al. Among authors: scemama m. Can J Cardiol. 2023 Oct;39(10):1315-1324. doi: 10.1016/j.cjca.2023.04.018. Epub 2023 Apr 26. Can J Cardiol. 2023. PMID: 37116789 Free article.
33 results